ORDER

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi had published tender no. BPPI/Drugs- 050/2017 dated 25.05.2017 through e-procurement system for supply of drugs for the year 2017-2019.

Whereas, M/S Syncom Healthcare Ltd. (hereafter called as the firm) addressed at “502, ADVENT ATRIA, CHINCHOLI BUNGER ROAD, MALAD(WEST), MUMBAI- 400064, MAHARASHTRA had participated in tender. The firm was awarded 10 drugs by Bureau of Pharma Public Sector Undertakings of India, New Delhi vide Letter of acceptance dated 03/11/2017 for the period of 2 years as per tender provision. The firm was asked to supply the drug within 45 days against purchase order as per clause 12.4 (a) of tender document as per details below:-

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Purchase order no. &amp; date</th>
<th>Drug code</th>
<th>Description of Drug</th>
<th>Quantity</th>
<th>Delivery Period</th>
<th>Value of purchase order (including GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>18000211 dated 11.05.18</td>
<td>1</td>
<td>Aceclofenac 100mg and Paracetamol 325mg Tablet</td>
<td>750000</td>
<td>45 Days (Expired on 25.06.2018)</td>
<td>2640000/-</td>
</tr>
</tbody>
</table>

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi issued Show cause notice on 28/09/2018 to the firm informing about provisions of the clause no. 8.1 (iii) & (iv), 11 (e), 12.4 (d) & (e), 19.7 & 20.1(a) of tender document with request to explain within 7 days why not following actions against them may be taken:-

(i) Procure the drugs from the other sources at your risk and cost as per tender clause 12.4 (d) & (e) and recovery of extra expenditure shall be made from you.
(iii) Consider your bad performance for future dealings and disqualify your company from participating in the tender for the next 2 years.
(iv) Recover 5% value of supply order from your pending bill.
(v) Initiate blacklisting of your company.

Whereas, the firm vide their e-mail dated 05/10/2018 informed that they will execute the above purchase order as soon as API rates comes in normal. As the rates of API materials is 300 to 400% is higher than normal rates. The firm’s justification for non-supply of drug due to increase in rates of API is not covered under tender terms & conditions and not acceptable to BPPI in terms of tender provision.
In view of above, the firm is debarred for a period of 2 years to participate in the tender of Bureau of Pharma Public Sector Undertakings of India, New Delhi for supply of DC-1 (Acelofenac 100mg and Paracetamol 325mg Tablet) from date of issuance of this order besides recovery of 5% value of supply order from pending bills & forfeiture of performance security.

This order is without prejudice to the legal and criminal action to be taken if any, by Bureau of Pharma Public Sector Undertakings of India, New Delhi in the matter.

(Sachin Singh IRS)
Chief Executive Officer
Bureau of Pharma PSUs of India, New Delhi

To

Regd.

M/S Syncom Healthcare Ltd. (here after called as the firm) addressed at “502, ADVENT ATRIA, CHINCHOLI BUNDER ROAD, MALAD(WEST), MUMBAI- 400064, MAHARASHTRA"